Rinascera Therapeutics develops transformative therapies for rare genetic skin diseases, including RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic Epidermolysis Bullosa (DEB).
Rinascera Therapeutics develops transformative therapies for rare genetic skin diseases, including RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic Epidermolysis Bullosa (DEB).